March 12, 2015
Gene mutations may predict melanoma response to immunotherapies
Melanoma patients whose tumors test positive for mutations in the NRAS gene were more likely to benefit from new immunotherapy drugs, according to a new study led by Vanderbilt-Ingram Cancer Center (VICC) investigators.
By VUMC News and Communications